Posted inHematology-Oncology
Efficacy of Rituximab Combined with Pentostatin or Bendamustine in Multiply Relapsed Hairy Cell Leukemia: Insights from a Phase 2 Trial
This phase 2 trial reveals that both pentostatin-rituximab and bendamustine-rituximab combinations achieve high response rates exceeding rituximab alone in multiply relapsed or refractory hairy cell leukemia, with potential superiority trends favoring pentostatin-rituximab in selected patients.